Journal
DRUG DISCOVERY TODAY
Volume 24, Issue 5, Pages 1157-1165Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.03.015
Keywords
-
Categories
Funding
- State of Sao Paulo Research Foundation (FAPESP, Fundacao de Amparo Pesquisa do Estado de Sao Paulo), Brazil
- National Council for Scientific and Technological Development (CNPq, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico), Brazil
Ask authors/readers for more resources
In silico prediction of ADMET is an important component of pharmaceutical R&D. Last year, the FDA approved 59 new molecular entities, with small molecules comprising 64% of the therapies approved in 2018. Estimation of pharmacokinetic properties in the early phases of drug discovery has been central to guiding hit-to-lead and lead-optimization efforts. Given the outstanding complexity of the current R&D model, drug discovery players have intensely pursued molecular modeling strategies to identify patterns in ADMET data and convert them into knowledge. The field has advanced alongside the progress of chemoinformatics, which has evolved from traditional chemometrics to advanced machine learning methods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available